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ABSTRACT
Introduction Melasma is a pigmentation disorder of
the skin. Characterised by brown to gray-brown patches
on the face and neck, the condition predominantly
affects women and has been associated with pregnancy,
hormonal variation and sun exposure. Melasma can be
disfiguring and anxiety-provoking, and quality of life is
often adversely impacted. Management includes sun
protection, laser and energy device therapy, topical
and oral skin-bleaching agents and chemical peels.
While clinical trials of melasma exist, there is a lack of
consistency in reported outcomes, which has been a
barrier to the aggregation of data in systematic reviews
and meta-analyses. This protocol describes a planned
process for development of a minimum set of outcomes
(ie, ‘core outcome set’) that should be measured in all
clinical trials of melasma.
Methods and analysis An exhaustive list of potential
outcomes will be extracted from four sources: (1)
systematic literature review of outcomes in clinical trials;
(2) semistructured patient interviews; (3) brochures,
pamphlets, clinical trial registries, and other published
and unpublished sources and documentation; and (4)
interviews with non-patient, non-physician stakeholders,
including federal regulators, industry scientists and non-
physician providers. An international two-round Delphi
process will then be performed to identify the outcomes
deemed most important to patients and physicians.
Subsequently, a consensus meeting will be convened to
review and process the results, and to vote on a final set of
core outcomes.
Ethics and dissemination Ethics approval was provided
by the Northwestern University Institutional Review Board
(protocol ID: STU00201637). This study is registered with
both the Core Outcome Measures in Effectiveness Trials
and Cochrane Skin-Core Outcome Set Initiative initiatives,
and this protocol is in accordance with the guidelines for
protocol development of both groups. All findings from the
study described in this protocol will be disseminated to all
stakeholders involved in the development process and will
be submitted for publication in peer-reviewed journals.
PROSPERO registration number CRD42020214189.
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INTRODUCTION
Melasma is a chronic hyperpigmentation
disorder primarily occurring in women.1 2 The

Strengths and limitations of this study
► This protocol describes a planned process for the

►

►

►

►

development of a minimum set of outcomes (ie,
‘core outcome set (COS)’) that should be measured
in all clinical trials of melasma.
A long list of potential outcomes will be extracted
from a systematic literature review, semistructured
interviews, brochures and pamphlets, clinical trial registries and other published and unpublished
sources and documentation.
An international group of stakeholders, including
patients, physicians, federal regulators, industry scientists, pharmacologists and pharmacists, nurses
and non-physician providers will be included in the
process.
At least two rounds of Delphi process will then be
performed to identify a provisional list of outcomes
meeting a 70% consensus level for patient and physicians, followed by the convening of a consensus
meeting to review and process the results, and to
vote on a final set of core outcomes.
This COS will establish ‘what’ should be measured,
but not ‘how’ or ‘when,’ which will be defined in
later development of core outcome measure set for
melasma.

condition is characterised by brown, irregularly shaped macules and patches, commonly
of the bilateral upper cheeks, mid forehead
and upper lip. Predisposing risk factors for
the development of melasma include darker
skin types III and IV, genetic predisposition,
ultraviolet radiation and hormonal changes
due to pregnancy, menopause or medications.3–5 However, melasma remains a poorly
understood condition that also arises in the
absence of traditional risk factors, with a
significant minority of cases occurring in
men.6 Histologically, there is an increase
of melanocytes and solar elastosis in the
epidermis of melasma lesions compared with
normal skin.2 4 7 Due to its sometimes striking
impact on cosmetic appearance, melasma can
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cause psychological distress, thereby negatively affecting
quality of life (QoL).3
Melasma is typically divided into three subtypes
(epidermal, dermal or mixed) and can be classified via
Wood’s Lamp examination. Severity of lesions and area
of involvement can be assessed using validated or more
ad hoc measurement tools. Melasma has been treated
with various modalities, including lasers and lights, chemical peels, skin-bleaching agents, such as hydroquinone,
or oral agents, like tranexamic acid.1 8 However, current
treatments are of limited efficacy and recurrence is the
norm. Additionally, extant studies seldom assess patient-
reported outcomes, which are particularly relevant given
the disfiguring nature of melasma.
Systematic reviews of treatments for melasma are
limited in utility by the lack of standardisation in outcomes
across trials.8 The selective inclusion of outcomes in
publications, so-called selective outcome reporting bias,
remains a problem in the reporting of clinical trials. In
particular, the heterogeneity of outcomes reported across
trials may affect the recommendations and conclusions
of systematic reviews.9 In order to address the heterogeneity of outcomes in clinical trials of the same disease or
condition, The Core Outcome Measures in Effectiveness
Trials (COMET) initiative was created, with the goal of
providing methodological support to facilitate development of standardised core outcome sets (COS) to be
measured in health-related research.10 A COS is defined
as a consensus-derived set of outcomes that are measured
at minimum in all clinical studies of a given condition
or disease. Similarly, another group, the Cochrane Skin-
Core Outcome Set Initiative (CS-COUSIN), was developed specifically to address COSs in dermatology.11
CS-
COUSIN provides methodological support, and
much of its approach is based on the experience of the
Harmonising Outcome Measures for Eczema (HOME)
initiative.12–16
To date, there has been no COS published specifically
for melasma. The data obtained from the investigation
described in this protocol will define the minimum set of
outcomes that should be reported in future clinical trials
of melasma interventions.

This COS will establish ‘what’ should be measured,
but not ‘how’ or ‘when,’ which will be defined in a later
consensus study specific to outcome measures.

METHODS AND ANALYSIS
This study was designed using guidance provided by the
CS-COUSIN and COMET initiatives and has been registered with both organisations.17–20 Additional guidance
was provided by the HOME roadmap.16 The reporting
of this protocol conforms to the The Core Outcome
Set-
STAndardised Protocol Items Statement checklist and the CS-
COUSIN Core Domain Development
Process guidance.18 21 This protocol is also based on
prior work in protocol development by the Measurement
of Priority Outcome Variables in Dermatologic Surgery
(IMPROVED) Group, a COS development organisation
for dermatological surgery-related conditions.22
Study oversight
The international study steering committee developing
this COS will include four physicians (MA, IAM, JFS
and TVC) as well as a patient representative. The latter,
who will also have melasma, will represent others with
this condition by providing input at key points to ensure
that the patient perspective is incorporated. The four
physicians have prior experience in developing COSs
in dermatology, and therefore, also act as researchers in
COS development. The steering committee will lead each
stage of COS development and ensure methodological
quality throughout the study. In addition, an independent member of the CS-COUSIN Methods Group (JJK)
will provide guidance on the most current methodological recommendations for COS development.

Scope of this COS
This COS is envisioned as the global standard for all clinical trials examining the efficacy and safety of all melasma
interventions, including both early and late phase trials.
The COS to be developed is intended to apply to all
individuals with melasma, regardless of age, gender and
ethnicity.

Study design
Identification of outcomes
A long list of outcomes will be generated from four
sources. First, a systematic review of the literature,
which has been registered prospectively with the International Prospective Register of Systematic Reviews
(PROSPERO, CRD42020214189), will be performed to
identify and extract outcomes measured in randomised
controlled trials of melasma. Specifically, with the help of
a medical librarian, PubMed/Medline and Embase will
be searched for the period 2006–2016 to detect English
language human RCTs including, but not limited to,
the following terms: [(melasma [title/abstract]) AND
(randomized controlled trial [publication type]) AND
(treatment OR therapy OR therapeutics)]. RCTs will be
used to identify outcomes of interest, since it is usual and
customary in COS methodology to focus on RCTs when
they are available in sufficient variety and quantity.23–26
Inclusion criteria will be studies that: (1) are randomised
and controlled; (2) assess the efficacy and/or safety of
one or more interventions for treatment of melasma;
(3) are available in the English language and (4) and
involve human subjects. Articles will be excluded if they:
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Objective
The aim of this study will be to develop a COS through
an international consensus process, for use in future clinical trials of melasma. The objective is to determine what
outcomes should be reported as a minimum in future
clinical trials of melasma.
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(1) were published as a poster or conference abstract; or
(2) the full text of the article is unavailable. Articles will
be independently screened for eligibility by two investigators, and disagreements will be resolved by a third
investigator. Two independent reviewers will then extract
outcomes from individual studies. During extraction,
QoL outcomes will be separated into distinct categories
to ensure all of the various components of QoL that have
been measured in previous investigations are included as
possible core outcomes. Outcome measures will also be
extracted during this step, and this data will be recorded
for the future development of a core outcome measure
set for melasma.27 The results of the systematic review will
be published separately from the COS.
Second, other printed and electronic sources, including
clinical trial registries (
ClinicalTrials.
gov searched for
‘melasma’, 2017–2021, no exclusion criteria), patient
pamphlets (American Academy of Dermatology website
searched for ‘melasma’, with inclusion criteria being ‘all
patient education material’, and no exclusion criteria.)
medical society brochures and relevant US Food and
Drug Administration/European Medicines Agency guidance documents, will be reviewed to identify any additional outcomes not detected in the systematic review.
Third, outcomes valued by patients will be identified
by conducting semistructured interviews with patients
diagnosed with melasma. These interviews will be audio
recorded, transcribed and analysed by the methods of
qualitative research to find outcomes considered relevant by patients. Fourth, semistructured interviews
will be performed to identify any remaining outcomes
deemed relevant by representatives of key non-physician,
non-
patient stakeholder classes, including industry
scientists,(Leaders at a purposive sample of large,
medium-sized and small US drug, device, and cosmetic
companies involved in research on products for melasma
will be contacted to ask for identification of qualified
industry scientists in their employ who can help identify
additional outcomes. In total, up to 20 industry scientists
will be contacted. Drug and device safety regulators from
the countries most represented in the systematic review
will be contacted for interviews. When their names are
publicly available, officials from dermatology or cosmetic-
related offices within these regulatory agencies will
be contacted first). pharmacologists and pharmacists,
drug and device safety regulators, (US Food and Drug
Administration, European Medicines Agency, Ministry
of Food and Drug Safety (Korean), Pharmaceuticals
and Medical Devices Agency (Japan), Health Canada,
Brazilian Health Regulatory Agency (ANVISA)), nurses
and physician assistants. Semistructured interviews with
patients and other stakeholders will be conducted by
investigators who have been trained in this qualitative
research technique. Specifically, such interviews will be
comprised of a series of open-ended questions, followed
by pre-established prompts, in the event that respondents
are unclear as to the primary question. At the end of
the semistructured interview, stakeholders will be asked
Ibrahim SA, et al. BMJ Open 2022;12:e046953. doi:10.1136/bmjopen-2020-046953

to volunteer any additional information about the topic
that they may wish to share. Interviewers will be strictly
prohibited from using off-script leading questions that
may bias data collection. After the semistructured interviews are completed, they will be transcribed, and the
iterative methods of qualitative methods will be used to
extract common themes. These themes, if not already
present in the list of outcomes, will then be used to create
new outcomes that will be appended to the long list. Non-
physician, non-patient stakeholders will not be invited to
participate in the subsequent Delphi process but will be
invited to the final consensus meeting.
Final review of long list of outcomes
The outcomes obtained from the sources above will be
collated into a long list of provisional outcomes. Members
of the steering committee will review and condense this
list, eliminating duplicate items and combining items
when possible, without loss of content. In accordance
with the proposed definition of a unique outcome by
Young et al, unique outcomes (ie, outcomes with ‘original meaning and context’) will be preserved, and other
outcomes (ie, those ‘with different words, phrasing or
spelling addressing the same concept and context’) will
be lumped together.28 The list of outcomes will then
be placed into appropriate domains by two steering
committee members using the COMET and CS-COUSIN
taxonomies.29 30 Lay definitions will be appended to all
outcomes and reviewed by the melasma steering group
patient representative to assure that patient stakeholders
can actively participate in the forthcoming Delphi
consensus process.
Delphi participants
Two separate groups, consisting of physicians and
patients, respectively, will be invited to take part in the
Delphi process. A global context will be provided by
inviting physicians from the USA and from other countries on various continents, including a range of ethnicities. To include the perspective of researchers, the
senior authors of all clinical trials extracted in our literature review will be included in the physician group.
Eligible physician stakeholders will include dermatologists, clinical researchers, primary care providers and
other medical specialists who have experience treating
melasma. Demographic information, including participants’ ethnicity, gender and specialty will be recorded.
To account for potential dropouts, at least 100 physicians
meeting any of the following criteria will be invited: corresponding author of a clinical trial of melasma included
in our systematic review; among the most frequently
published authors on melasma treatment, as identified
through electronic databases; recent lecturers on the
topic of melasma at national or international dermatology professional society meetings in any country; or
members of a national or international dermatological
society (Representative board members of the following
societies will be invited to participate as individuals in the
3
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Delphi to ensure inclusion of the perspectives of expert
clinicians and researchers who may not have recently
published in the literature: American Academy of Dermatology Association; American Society for Laser Medicine
and Surgery; African Society of Dermatology and Venereology; Asian Academy of Dermatology and Venereology;
Arab Academy of Dermatology and Aesthetics; Argentine Society of Dermatology; Brazilian Society of Dermatology; British Association of Dermatologists; Canadian
Dermatology Association; European Academy of Dermatology and Venereology; French Society of Dermatology;
Mexican Society of Dermatology; Skin of Colour Society;
World Congress of Dermatology). with clinical expertise
in melasma treatment, as demonstrated by committee or
other affiliations.
Physicians who agree to participate will be asked to
identify one or more melasma patients who may be
invited to join the patient Delphi group, with a goal of
15 patient stakeholders participating in the Delphi. All
recruitment will be done by our study team and will be
approved by our ethics committee. However, this will not
entail limiting patient recruitment from our site only,
since we will be asking physician Delphi participants
located elsewhere to volunteer patients who may choose
to participate in the study. Such patient volunteers will
contact the research staff at our site, who will consent
and enroll them, if appropriate. Additional methods will
be taken to ensure patient involvement throughout the
study, including: (1) specifying patient involvement in the
Institutional Review Board (IRB) protocol; (2) seeking
relevant input from patients; (3) maintenance of investigator open-mindedness to the patient perspective; (4)
careful reviewing of all outcomes with patient representatives; (5) thorough note taking; (6) taking time to reflect
on patient feedback and (7) identifying and engaging a
diverse group of patient participants.31
Modified Delphi process
From the long list of potential outcomes vetted by the
steering committee, a core set of outcomes will be provisionally selected by stakeholders through a Delphi process,
as recommended by the COMET and CS-COUSIN initiatives.17 18 30 Specifically, each Delphi participant will be
asked to rate each outcome for its level of importance on
a scale from 1 to 9. Average ratings for each outcome, and
relevant participant comments, will then be redistributed
to each survey participant, who will have the option of
changing his or her earlier ratings based on the additional
information surfaced in this process. Prior to a consensus
meeting, at least two Delphi rounds will be conducted.

important.’32 In each round, each participant will have
the option to select ‘10’ if they are uncertain about an
outcome’s need for inclusion. Also in each round, each
participant will have the option to identify new outcomes
that they feel should be added in the subsequent round.
All previously included outcomes will be carried to the
next round. Participants will have 3 weeks to complete
each Delphi round, and will receive weekly reminders
until they do, or time expires.
Results from round 1 will be analysed by outcome
and for each stakeholder group. Then, round 2 will
commence. In round 2, participants will be graphically
shown the distribution of scores for each item for each
stakeholder group from round 1, and also their own individual ratings for each outcome from the previous round,
and asked to score each item again. New outcomes will
be added to round 2 if suggested by two or more participants in round 1, if the steering committee determines
the suggested outcome(s) to be unique from existing
outcomes.28
Summarised scores from round 2, analysed by outcome
and for each stakeholder group, will be presented at the
consensus meeting. Attrition is possible between Delphi
rounds, and although numeric data (eg, mean, median
and range of scores) from round 2 alone will be analysed
and presented at the consensus meeting, written feedback from both rounds will be collated and discussed at
the consensus meeting, as well.
Definition of provisional consensus
Outcomes will be retained in the provisional consensus pool
if 70% of the participants score 7, 8 or 9 with less than 15%
scoring 1–3.33 Outcomes will be removed from the provisional consensus pool if 70% or more of the participants
score 1, 2 or 3 and less than 15% score 7–9. To avoid having
a COS that entails too many items, if the provisional list of
included outcomes is longer than expected, participants at
the consensus meeting will be urged to further refine and
abbreviate this list. The definition of consensus is based on
previous, published COS consensus methodology and guidance of the COMET Methodology Group.17 34–36 Outcomes
that have not reached consensus will also be retained for
discussion during the consensus meeting.

Delphi rounds
During each Delphi round, the provisional outcomes
in the long list will be presented to each participant for
rating. Participants will rate each outcome on a 9-point
scale developed by the Grading of Recommendations
Assessment, Development and Evaluation working group,
with ‘9’ denoting ‘critically important’ ‘and ‘1,’ ‘not that

Consensus meeting
A series of virtual consensus meetings will be held to discuss
the results of the Delphi, to review the provisional COS as
well as the outcomes for which consensus has not been
reached, and to move towards selection of a final COS.
The reason to have more than one consensus meeting is
to avoid the scenario in which the loudest voices dominate, and patients in particular are not heard as clearly
and to the extent that they should be. Since we anticipate
30–60 healthcare professionals, and approximately five
patients to participate in the process, we anticipate three
virtual consensus meetings of 15–20 participants each,
with each meeting also including patient participants.
An additional benefit of having multiplate consensus
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meetings is that different schedules and time zones can be
accommodated. Finally, if the outcomes of the different
consensus meetings are not fully consistent, an email
ballot will be sent to all participants individually to resolve
any remaining issues. Each meeting will be moderated by
an independent facilitator, and invited participants will
include all physicians and patients who participated in at
least the first round of the Delphi. Each meeting will have
balanced representation across stakeholder groups and
geographical regions to ensure the result is development
of a global COS. Other non-physician, non-patient stakeholders will be invited, as well.
Informed by the Delphi results, feedback regarding the
consensus-derived set of provisional outcomes and outcomes
for which consensus has not been reached will be elicited
from the consensus meeting participants with the assistance
of the facilitator. Using live polling software, participants will
vote to include or not include outcomes into the final core
set of outcomes. If multiple consensus meetings are held, and
if there is any inconsistency between the outcomes selected
in these, a final email ballot will be circulated to all consensus
meeting participants to confirm the final COS. The result
will be a COS that reflects the priorities and concerns of all
stakeholders.
Timeline
The expected timeline from the start of the study to full
development of the core set of outcome domains will be
18–24 months. Identification of an initial list of outcomes,
via systematic review followed by qualitative interviews,
will span approximately 7–8 months. An additional seven
to ten months will be dedicated to conducting the Delphi
survey and convening the consensus meeting, followed
by approximately 4–6 months for analysing feedback and
drafting, circulating and finalising the manuscript.
Patient and public involvement
The patient and public perspective will be sought at
multiple points in this study. Patient stakeholders will
review plain language summaries of outcome definitions. A minimum of one patient representative will be
included in the research team, as described earlier in
this protocol. Additionally, patients will be recognised
as key stakeholders during the identification and prioritisation of outcomes, with fully one-half of the Delphi
process reserved for patients. Patients will be encouraged to provide feedback before (semistructured interviews), during and after (at the consensus meeting) the
Delphi process to ensure that patient-centred outcomes
are incorporated. Lastly, with their consent, patient representatives will be named as contributors in any published
work that arises from the study.
ETHICS AND DISSEMINATION
Dissemination and implementation of results
The full development of this COS and the results of the
reviewed journals. The
study will be reported in peer-
Ibrahim SA, et al. BMJ Open 2022;12:e046953. doi:10.1136/bmjopen-2020-046953

main results of the study, including the COS, will be
disseminated to all participants through email at the time
of study publication. Researchers will be encouraged to
use the COS when performing future trials.
Ethical approval and consent to participate
Ethical approval and consent to participate for the study
has been granted from the Northwestern University IRB
(protocol ID: STU00201637). Informed consent will be
presented before registering for the Delphi. The Northwestern University IRB has waived written informed
consent and has approved verbal consent for interviews,
and online consent for the Delphi process.
DISCUSSION
Despite the numerous completed and ongoing clinical
trials of treatments for melasma, there is currently no
COS informing such investigations. The proposed COS
for melasma would provide a minimum set of outcomes
to be reported in all trials of melasma, thus standardising
future outcomes reporting. Investigators would be free
to consider and include additional outcomes beyond the
core set, but their use of at least the core set would allow
aggregation and comparison of data across melasma
trials. Cross-trial comparisons of treatments and large-
scale meta-analyses would, in turn, enable more definitive
conclusions on the merits of available treatments.
Trial registration and status
This study has been registered with both the COMET and
CS-COUSIN initiatives for COS development, and the
development of this protocol is in accordance with the
guidelines for protocol development of both groups. The
development of the COS is currently in its initial phase of
outcome extraction.
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